Brokers Offer Predictions for INKT Q3 Earnings

MiNK Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright forecasts a Q3 2026 loss of $0.67 per share for MiNK Therapeutics and maintains a Buy rating with a $38 price target. It estimates full-year 2026 loss at $2.58 per share.
  • Analyst opinions are mixed: two rate INKT Buy, one Hold, and one Sell, resulting in a consensus Hold rating and $44 average price target. B. Riley raised its target to $50, while Zacks downgraded the stock to Hold.
  • MiNK’s most recent reported quarter came in below expectations, with a $0.62-per-share loss versus the $0.60 consensus estimate. Shares opened at $9.94, within a 12-month range of $8.48 to $16.93.
  • MarketBeat previews top five stocks to own in December.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for shares of MiNK Therapeutics in a research report issued to clients and investors on Wednesday, November 4th. HC Wainwright analyst M. Keller anticipates that the company will earn ($0.67) per share for the quarter. HC Wainwright has a "Buy" rating and a $38.00 price target on the stock. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for MiNK Therapeutics' Q4 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.58) EPS.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02).

A number of other brokerages also recently commented on INKT. Zacks Research downgraded MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of MiNK Therapeutics in a research note on Friday, October 2nd. Finally, B. Riley Financial reaffirmed a "buy" rating and issued a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, MiNK Therapeutics presently has an average rating of "Hold" and a consensus price target of $44.00.

View Our Latest Stock Report on MiNK Therapeutics

MiNK Therapeutics Stock Performance

NASDAQ INKT opened at $9.94 on Friday. The firm has a 50-day simple moving average of $11.26 and a 200 day simple moving average of $11.27. MiNK Therapeutics has a twelve month low of $8.48 and a twelve month high of $16.93. The stock has a market cap of $50.72 million, a PE ratio of -4.14 and a beta of 0.49.

Insider Buying and Selling at MiNK Therapeutics

In other news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the transaction, the chief executive officer directly owned 74,195 shares of the company's stock, valued at approximately $783,499.20. This represents a 8.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 20.40% of the company's stock.

MiNK Therapeutics Company Profile

(Get Free Report)

MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company's platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK's lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.

Featured Articles

Earnings History and Estimates for MiNK Therapeutics (NASDAQ:INKT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MiNK Therapeutics Right Now?

Before you consider MiNK Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.

While MiNK Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines